Canvas Inc.

Established in Toyota City, Aichi Prefecture, to conduct research and development of a novel anticancer agent with minimal impact on normal cells, based on findings related to the G2 checkpoint.

Established CanBas Co., Ltd. in Toyota City, Aichi Prefecture, in 2000.

Established CanBas Co., Ltd. in Toyota, Aichi.

Opened a research laboratory within the incubation facility attached to the Shizuoka Numazu Industrial Technology Center in Ōoka, Numazu City, Shizuoka Prefecture.

Established a research institute in Numazu City, Shizuoka Prefecture.

Set up the Laboratory in Numazu, Shizuoka.

Established a Scientific Advisory Board (SAB).

Relocated the headquarters and research laboratory to Tōyōchō, Numazu City, Shizuoka Prefecture, and established an animal testing facility within the Shizuoka Numazu Industrial Technology Center.

Relocated headquarters and research institute to Toriyoko‑cho, Numazu City, Shizuoka Prefecture; established an animal testing facility within the Numazu Industrial Technology Center, Shizuoka Prefecture.

Initiated a Phase 1 clinical trial of CBP501 monotherapy in the United States.

Initiated a single-agent Phase 1 clinical trial of CBP501 in the United States.

Initiated CBP501 single-drug Phase 1 clinical study in the US.

Moved the animal testing facility from the incubation facility attached to the Shizuoka Numazu Industrial Technology Center to a site adjacent to the headquarters in Tōyōchō, Numazu City, Shizuoka Prefecture.

Commenced a Phase 1 clinical trial of the combination of CBP501 and cisplatin in the United States.

Initiated a Phase 1 clinical trial of CBP501 in combination with cisplatin in the United States.

Initiated CBP501 Phase 1 clinical study in two drug combinations with Cisplatin in the US.

Entered into a joint venture agreement with Takeda Pharmaceutical Company Limited regarding CBP501 and its backup compounds.

Entered into a joint development agreement with Takeda Pharmaceutical Company for CBP501.

Entered into CBP501 Joint Development Agreement with Takeda.

Initiated CBP501 Phase 1 clinical study in three drug combinations with Cisplatin and Pemetrexed in the US.

Started a Phase 1 clinical trial of the triple combination of CBP501, cisplatin, and pemetrexed in the United States.

Initiated a phase 2 clinical trial of CBP501 in combination with cisplatin and pemetrexed in the United States.

Initiated a Phase 2 clinical trial of the triple combination of CBP501, cisplatin, and pemetrexed for malignant pleural mesothelioma in the United States.

Initiated a phase 2 clinical trial of CBP501 in pleural mesothelioma patients in the United States (combination with cisplatin and pemetrexed).

Initiated CBP501 Phase 2 clinical study in patients with MPM in three drug combinations with Cisplatin and Pemetrexed in the US.

Commenced a Phase 1b trial of the combination of CBP501, cisplatin, and nivolumab (Opdivo).

Initiated a phase 2 clinical trial in the United States combining CBP501, cisplatin, and pemetrexed for non‑small cell lung cancer.

Listed shares on the Tokyo Stock Exchange Mothers market.

Listed on the Tokyo Stock Exchange Mothers market.

Went public on the Tokyo Stock Exchange Mothers Market.

Completed enrollment for the expansion phase of the Phase 2 clinical trial of CBP501 targeting pancreatic cancer.

Presented Phase 1b trial data of CBP501 at ASCO.

Terminated the joint development agreement for CBP501 with Takeda Pharmaceutical Company.

Terminated the joint commercialization agreement with Takeda Pharmaceutical Company concerning CBP501 and its backup compound.

Terminated CBP501 Joint Development Agreement with Takeda Pharmaceutical Co., Ltd.

Relocated the headquarters, research laboratory, and animal testing facility to Otemachi, Numazu City, Shizuoka Prefecture (current location).

Consolidated headquarters, research institute, and animal testing facility and relocated to Ohtemachi, Numazu City, Shizuoka Prefecture (current location).

Received orphan drug designation from the U.S. FDA for CBP501 targeting mesothelioma.

CBP501 received orphan drug designation from the U.S. FDA (eligible for MPM).

CBP501 received orphan drug designation from FDA for MPM.

Announced at ASCO that CBP501 achieved the primary endpoint in the Phase 2 clinical trial for malignant pleural mesothelioma.

Achieved the primary endpoint in the phase 2 clinical trial of CBP501.

CBP501 achieve the primary endpoint of the Phase 2 clinical study in patients with Malignant Pleural Mesothelioma (MPM).

Published preliminary results of the Phase 2 clinical trial of CBP501 for non‑small cell lung cancer. Although the primary endpoint was not met, a significant effect was suggested in a key secondary endpoint in a specific patient subgroup.

Published preliminary data from a phase 2 clinical trial of CBP501 in patients with non‑small cell lung cancer (NSCLC).

Published preliminary data from CBP501 Phase 2 clinical study in patients with Non Small Cell Lung Cancer (NSCLC).

Signed a licensing agreement with Stemline Corporation in the United States regarding CBS9106.

Granted a license for CBS9106 to Stemline (excluding Japan, China, Taiwan, and South Korea).

Granted CBS9106 license (except for Japan, China, Taiwan and South Korea) to Stemline.

Entered into a joint research agreement with the University of Tokyo Hospital (National University Corporation) for pharmacological efficacy testing using a pancreatic cancer induction model mouse.

Started a Phase 1 clinical trial targeting solid tumors with CBS9106 (development code SL-801, generic name Felezonexor) in partnership with Stemline.

Stemline commenced a phase 1 clinical trial of CBS9106 (SL‑801) for solid tumors.

Stemline initiated CBS9106 (SL-801) Phase 1 study for solid tumors.

Entered into a joint research agreement with the Shizuoka Prefecture Industrial Promotion Foundation (Pharma Valley Project) for drug discovery screening using a compound library.

Entered into a joint research (screening) agreement with Fuji Pharmaceutical.

Joint Research (screening) Agreement with Fuji Pharma Valley Project.

Entered into a joint research agreement with the Shizuoka Prefecture Industrial Promotion Foundation (Pharma Valley Project) regarding IDO/TDO inhibitors.

Signed a joint research agreement with Shizuoka University for IDO/TDO.

IDO/TDO Joint Research Agreement with University of Shizuoka.

CBP501 Phase 1b data published at ASCO.

Initiated a Phase 1b trial combining CBP501, cisplatin, and nivolumab (Opdivo).

Initiated a phase 1b clinical trial of CBP501 (dose‑escalation cohort) in the United States (combination with cisplatin and nivolumab).

Initiated CBP501 Phase 1b clinical study (dose finding cohort) with CDDP and nivolumab combination in the US.

Modified the license agreement with Stemline for CBS9106, expanding the target region to worldwide, including Japan, China, Taiwan, and South Korea.

Granted a global license for CBS9106 to Stemline.

Granted CBS9106 global license to Stemline Therapeutics, Inc.

Completed enrollment of the pancreatic cancer cohort in the expanded Phase 1b trial of CBP501.

Presented Phase 1b trial data of CBP501 at ASCO.

Presented phase 1b data of CBP501 at ASCO.

Received grant funding for the 2020 (Reiwa 2) Medical Device Industry Infrastructure Strengthening Project focusing on COVID-19 therapeutics targeting immune responses.

Received approval from the U.S. FDA to commence a phase 2 clinical trial targeting third‑line treatment for pancreatic cancer with CBP501.

Opened a clinical site for the phase 2 trial of CBP501.

CBP501 Phase 2 clinical trial site FPI (first patient enrollment)

Completed a Phase 1 clinical trial targeting solid tumors with CBS9106 (development code SL-801, generic name Felezonexor) in partnership with Stemline.

Moved from the Mothers market to the Growth market of the Tokyo Stock Exchange due to a review of market classifications.

Extended the terms of the joint research agreement with the University of Tokyo.

Obtained a patent for IDO/TDO inhibitors from the Japan Patent Office.

Received approval from the U.S. FDA to commence Phase 2b clinical trials of CBP501.

CBP501 designated as an orphan drug by the European Medicines Agency (EMA).